Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy

AUTOR(ES)

Storey, DJ, McLaren, DB, Atkinson, MA, Butcher, I, Frew, LC, Smyth, JF, Sharpe, M

FONTE

International braz j urol

DATA DE PUBLICAÇÃO

2011-12

RESUMO

Documentos Relacionados

• Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer
• Editorial Comment: Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
• Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy
• Long-Term Oxygen Therapy
• Another hormone-sensitive triglyceride lipase in fat cells?